New once-daily pill aims to simplify diabetes care in china
NCT ID NCT07441187
First seen Feb 28, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study will test a new once-daily tablet that combines three diabetes drugs (henagliflozin, retagliptin, and metformin) in about 300 Chinese adults with type 2 diabetes. The goal is to see how well it controls blood sugar and its safety over 24 weeks. Participants include newly diagnosed patients and those not well-controlled on one other diabetes medicine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.